2019/12/17 by Alicja Kalinowska, Mahboobeh Fereidan-Esfahani, Yong Guo +2 · 1 citation
Medicine · Neuroscience · #Peripheral Neuropathies and Disorders #Multiple Sclerosis Research Studies #Hereditary Neurological Disorders
paper · doi:10.1177/1352458519894710
openalex publication_date 2019/12/17 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/25
BACKGROUND: Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders. OBJECTIVE: To determine whether infliximab-associated central nervous system (CNS) demyelination can be differentiated from multiple sclerosis (MS). METHODS: We present a case of pathologically proven CNS demyelination in a patient treated with infliximab and describe clinical-radiographic-neuropathological findings. Putative mechanisms of TNF-alpha inhibitor-associated CNS demyelination are described. RESULTS AND CONCLUSION: Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS.